XSHE
300012
Market cap3.34bUSD
Jul 10, Last price
13.53CNY
1D
0.37%
1Q
-11.63%
Jan 2017
134.29%
IPO
489.83%
Name
Centre Testing International Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Centre Testing International Group Co. Ltd. (CTI) delivers a comprehensive suite of testing, calibration, inspection, certification, and technical services, operating across China and globally. The company's operations are divided into four key segments: Life Science, Trade Guarantee, Consumer Goods, and Industrial Test. CTI's extensive service portfolio includes specialized testing for hazardous substances, general safety, electromagnetic compatibility (EMC), and environmental safety. They also perform reliability and failure analysis for electronics and various materials (both metallic and nonmetallic), alongside dedicated product testing for textiles, footwear, leather goods, toys, and automotive materials and components. Furthermore, CTI offers in-depth testing, inspection, and compliance checks for food products, pharmaceuticals, cosmetics, animal feed, and food contact materials. Additional services encompass auditing, precise measurement calibration, dimensional inspection, semiconductor testing, management of hazardous materials in maritime shipping, freight assessment, certification programs, training courses, and the development and testing of application software. The company serves a broad spectrum of industries, including electrical and electronic products, building materials and engineering, maritime, metrology, food and drug, vehicle manufacturing, metal materials and parts, as well as hardline goods, toys, textiles, footwear, and leather products. Established in 2003, Centre Testing International Group Co. Ltd. is headquartered in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||